Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

New Bcl-2 Inhibitor Data At ASCO

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Apoptosis
Apoptosis-focused Ascentage also tapping into TPD area, where it hopes to progress a p53-MDM2 targeted asset into Phase I next year. (Shutterstock)
Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from China

More from Therapy Areas